24/7 Wall Street
20 Aug 2026, 11:35 UTC · 1h ago
Moderna's Newfound War Chest Opens Door for 4 Strategic Acquisition Targets
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
20 Aug 2026, 11:35 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Moderna's stock price surged 176.9% in a single session to reach a market capitalization of approximately $69.6 billion. — A massive re-rating of a major biotech player significantly increases its acquisition currency and market influence.
+0.80Moderna faces $1.3 billion in contingent patent exposure to Arbutus Biopharma, making an acquisition of ABUS a strategic way to eliminate this legal risk. — Acquiring the IP holder would remove a material financial liability and flip Moderna from defendant to enforcer in LNP litigation.
+0.60Intellia Therapeutics' Phase 3 lonvo-z trial showed an 87% reduction in hereditary angioedema attacks, with a U.S. launch targeted for H1 2027. — Strong Phase 3 data increases the asset's value and makes NTLA a highly attractive clinical target.
+0.50Continue reading
6 related stories
Top 3 movers · tap to explore
Editas Medicine's EDIT-401 showed >90% reductions in LDL-C, Lp(a), and ApoB in primates, with topline data expected in 2027. — Positive early-stage data in the cardiometabolic space creates a low-cost entry point for Moderna to diversify its pipeline.
+0.40Moderna expects a year-end 2026 cash and investments balance between $4.7 billion and $5.2 billion, plus a $0.9 billion credit facility. — Strong liquidity provides the necessary firepower to execute the M&A strategies discussed in the text.
+0.30Which stocks this story touches
The stock experienced a massive 177% surge and is positioned as a strong bidder for acquisitions.
Positive Phase 3 results showed an 87% reduction in attacks for its lead candidate.
Positive pre-clinical data in non-human primates and viewed as an attractive, low-cost acquisition target.
Discussed as a strong acquisition candidate with positive Phase 3 trial progress.
Highlighted as a prime acquisition target for Moderna to eliminate patent exposure.
Mentioned as being in litigation with Arbutus and Genevant over LNP IP.
Mentioned as being in litigation with Arbutus and Genevant over LNP IP.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Globe News Wire
3h ago
[mutual] Moderna and Immatics have an existing collaboration for a shared antigen candidate.
[mutual] Arbutus is litigating against Pfizer in 21 countries regarding LNP IP.
